# Summit Therapeutics (SMMT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SMMT
## Company Profile
- Ticker: SMMT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom with U
- Tags: Oncology
## Stock Data
- Close: 17.17 USD
- Market cap: 11533776904.699999 USD
- Last updated: 2026-10-08
## Business Overview
### Oncology-Focused Biopharmaceutical Company
Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF. The company holds development and commercialization rights in the United States, Canada, Europe, Japan, and selected other territories through its partnership with Akeso.
### Dual PD-1 and VEGF Mechanism
Ivonescimab combines immune-checkpoint blockade with anti-angiogenic activity in a single molecule. Its tetravalent design is intended to concentrate VEGF inhibition in the tumor microenvironment while preserving the antitumor immune activity associated with PD-1 blockade.
### Broad Lung Cancer Program
The development program spans EGFR-mutated non-small cell lung cancer after tyrosine kinase inhibitor therapy and first-line squamous and nonsquamous disease. Multiple global Phase 3 studies are evaluating ivonescimab with chemotherapy or as part of other treatment combinations.
### Expansion Across Solid Tumors
Summit is exploring ivonescimab beyond lung cancer through external combination studies and additional tumor types, including colorectal and head and neck cancers. Collaborations with other oncology companies provide access to complementary mechanisms without requiring Summit to internally own every combination asset.
### Partner-Enabled Global Development
Akeso retains rights in China and other licensed territories and provides an extensive clinical dataset from its own studies. Summit uses those data, together with global trials conducted under its rights, to support regulatory submissions and commercial planning in major Western markets.
## Why The Stock Is Moving

As of Oct 8, 2026, SMMT closed down 4.35% at $17.17. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA decision for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer on November 14, 2026.
- Final progression-free-survival analysis and interim overall-survival analysis from the squamous HARMONi-3 cohort in the second half of 2026.
- Progression-free-survival and interim overall-survival analyses from the nonsquamous HARMONi-3 cohort in the first half of 2027.
- Initial data from the Arcus-sponsored ivonescimab combination study around mid-2027.

## Recent News
- 2021-05-18 11:00 EST — [Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority](https://biopharmsignal.com/news/SMMT/summit-therapeutics-announces-preclinical-candidate-and-associated-carb-x-fundin-49a26b67) — Source: Summit Therapeutics
- 2021-05-17 12:00 EST — [Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021](https://biopharmsignal.com/news/SMMT/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-f-ffbe4e0b) — Source: Summit Therapeutics
- 2021-05-12 18:59 EST — [Summit Therapeutics Announces Closing of $75 Million Rights Offering](https://biopharmsignal.com/news/SMMT/summit-therapeutics-announces-closing-of-75-million-rights-offering-883ec93f) — Source: Summit Therapeutics
- 2021-05-06 12:00 EST — [Summit Therapeutics Publishes Scientific Updates to Corporate Website](https://biopharmsignal.com/news/SMMT/summit-therapeutics-publishes-scientific-updates-to-corporate-website-794c7590) — Source: Summit Therapeutics
- 2021-05-05 16:47 EST — [Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering](https://biopharmsignal.com/news/SMMT/summit-therapeutics-rights-offering-nearing-expiration-date-robert-w-duggan-decl-cbdf96f2) — Source: Summit Therapeutics